Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Tria

GuruFocus News 10/12/2026 15:59 On October 12, 2026, Syndax Pharmaceuticals Inc (NASDAQ: SNDX) saw its shares decline roughly 15% in after-hours trading following the announcement that its idiopathic pulmonary fibrosis (IPF) candidate, axatilimab, failed to meet the primary endpoint in a phase 2 clinical trial.

The study assessed the annualized rate of decline in forced vital capacity versus placebo, and the negative outcome weighed heavily on investor sentiment. SNDX’s current Price-to-Sales (P/S) ratio stands at 5.8, significantly below its historical median of approximately 74.9, signaling the market’s skepticism about future revenue growth; earnings-based valuation metrics like P/E are not applicable due to ongoing losses and negative cash flow.

The company’s GF ScoreTM is a low 27 out of 100, reflecting weak profitability and financial strength despite moderate momentum. Insider activity reveals no recent purchases and $2.7 million in insider sales over the past 12 months, while GuruFocus tracks two prominent gurus holding SNDX, with three trimming positions and only one adding shares recently.

What's Behind the News? The recent clinical trial setback for Syndax’s axatilimab in idiopathic pulmonary fibrosis is a significant blow to the company’s pipeline diversification efforts. Axatilimab, a CSF-1R-blocking antibody developed in collaboration with Incyte, was being evaluated for its ability to slow lung function decline in IPF patients.

Failure to achieve the primary endpoint dampens expectations for this asset’s commercial potential and may delay or reduce future revenue contributions from this indication. Syndax Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused primarily on oncology therapies, with a market capitalization of $1.48 billion.

Its lead product, revumenib (Revuforj), is an oral menin inhibitor approved for certain acute leukemias, while axatilimab is approved for chronic graft-versus-host disease. The company operates in the healthcare sector, specifically within the biotechnology industry, selling products mainly in the U.S. through a specialty oncology sales force and generating revenue from product sales, collaborations, and licensing agreements.

Is SNDX Overvalued on a Price-to-Sales Basis? Syndax’s current Price-to-Sales ratio of 5.8 is markedly lower than its roughly 74.9x historical median, indicating that the market is pricing in significantly slower revenue growth or increased risk going forward. This steep discount relative to history suggests investors are cautious about the company’s ability to expand sales, especially in light of recent clinical disappointments.

Compared to the biotechnology industry, where P/S ratios can vary widely, SNDX’s valuation reflects its distressed status and unprofitable operations. It is important to note that earnings-based valuation metrics such as the Price-to-Earnings ratio are not meaningful for Syndax, given its consistent net losses and negative operating cash flow.

The company’s trailing twelve months (TTM) EPS stands at -$2.52, and it has a negative free cash flow yield of -14.94%. As such, investors rely more heavily on sales multiples and qualitative factors when assessing valuation. GuruFocus’s proprietary GF ValueTM metric currently cannot provide a reliable fair value estimate for SNDX due to the company’s unprofitable status and volatile fundamentals.

Nonetheless, the directional signal from GF ValueTM aligns with the market’s cautious stance. What Does SNDX's GF ScoreTM Tell Us? The GF ScoreTM aggregates multiple dimensions of a company’s financial health, including profitability, growth, financial strength, valuation, and momentum, to provide a holistic snapshot of investment quality.

Syndax’s GF ScoreTM of 27 out of 100 indicates significant challenges, particularly in profitability and financial stability, despite some positive momentum. Metric Rating (out of 10) GF ScoreTM 27/100 Financial Strength 2/10 Profitability 1/10 Valuation 2/10 Momentum 7/10 Syndax’s weakest areas are profitability and financial strength, with operating margins near -77% and net margins close to -88%, reflecting ongoing losses.

The company’s Altman Z-Score of -1.36 places it in the distress zone, raising concerns about bankruptcy risk within two years. Conversely, momentum ranks relatively higher at 7/10, suggesting some recent positive price action or trading interest despite fundamental weaknesses. Valuation remains low but is tempered by the company’s distressed profile.

For more detailed metrics and updates, visit the SNDX stock page . What Are Gurus and Insiders Doing with SNDX? GuruFocus tracks two prominent gurus currently holding Syndax Pharmaceuticals, with recent activity showing one guru adding to their position while three have trimmed shares in recent quarters.

This mixed guru ownership trend reflects cautious optimism tempered by risk concerns. Insider activity over the past 12 months reveals no insider purchases and insider sales totaling approximately $2.7 million, indicating insiders are net sellers. This combination of guru trimming and insider selling underscores the challenges Syndax faces in regaining investor confidence following clinical setbacks and financial distress signals.

What This Means for Investors For investors, Syndax Pharmaceuticals presents a complex risk-reward profile dominated by its unprofitable and cash-flow-negative status. The sharply reduced Price-to-Sales ratio relative to historical levels signals the market’s tempered expectations for revenue growth, especially after the recent clinical trial miss with axatilimab.

Earnings-based valuation metrics are not applicable, and the company’s low GF ScoreTM highlights fundamental weaknesses in profitability and financial strength. Meanwhile, insider selling and guru trimming further emphasize caution among informed stakeholders. Investors should carefully weigh these factors when considering exposure to SNDX’s biotechnology pipeline and commercial prospects.

Further insights and updated data can be found on the SNDX stock page and through the GuruFocus Stock Screener . Frequently Asked Questions What is SNDX's GF ScoreTM? SNDX’s GF ScoreTM is 27 out of 100, indicating weak overall financial health with particular struggles in profitability and financial strength, despite moderate momentum.

Is SNDX overvalued or undervalued? Based on its Price-to-Sales ratio of 5.8, which is well below its historical median near 74.9, SNDX appears undervalued relative to its own history. However, earnings-based valuation like P/E is not meaningful due to the company’s persistent losses.

What is SNDX's P/E ratio compared to historical? SNDX does not have a meaningful P/E ratio as it is unprofitable with a trailing twelve months EPS of -$2.52. Instead, financial strength metrics such as the Altman Z-Score indicate distress and elevated bankruptcy risk.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected] .

Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.